Search

Home > GRACEcast Lung Cancer Video > Is nindetanib a new agent worthy of becoming a new treatment for advanced NSCLC?
Podcast: GRACEcast Lung Cancer Video
Episode:

Is nindetanib a new agent worthy of becoming a new treatment for advanced NSCLC?
Category: Science & Medicine
Duration: 00:05:35
Publish Date: 2013-06-19 23:09:43
Description:

Dr. Nate Pennell from Cleveland Clinic reviews the LUME Lung-1 trial presented by Reck at ASCO 2013, of Taxotere with or without nindetanib (BIBF-1120), an anti-angiogenic multikinase inhibitor, in advanced NSCLC.
Total Play: 0